Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

Marc H Weiner, William Burman, Chi Cheng Luo, Charles A. Peloquin, Melissa Engle, Stefan Goldberg, Vipin Agarwal, Andrew Vernon

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Treatment regimens combining moxifloxacin and rifampin for drug-susceptible tuberculosis are being studied intensively. However, rifampin induces enzymes that transport and metabolize moxifloxacin. We evaluated the effect of rifampin and the human multidrug resistance gene (MDR1) C3435T polymorphisms (P-glycoprotein) on moxifloxacin pharmacokinetic parameters. This was a single-center, sequential design study with 16 volunteers in which sampling was performed after four daily oral doses of moxifloxacin (400 mg) and again after 10 days of combined rifampin (600 mg) and moxifloxacin. After daily coadministration of rifampin, the area under the concentration-time curve from 0 to 24 h (AUC0-24) for moxifloxacin decreased 27%. Average bioequivalence between moxifloxacin coadministered with rifampin and moxifloxacin alone was not demonstrated: the ratio of geometric means (RGM) of the moxifloxacin AUC0-24 was 73.3 (90% confidence intervals [CI], 64.3, 83.5) (total P value, 0.87 for two one-sided t tests). Peak moxifloxacin concentrations, however, were equivalent: the RGM of the maximum concentration of the drug in serum was 93.6 (90% CI, 80.2, 109.3) (total P value, 0.049). Concentrations of the sulfate conjugate metabolite of moxifloxacin were increased twofold following rifampin coadministration (AUC0-24, 1.29 versus 2.79 μg·h/ml). Concomitant rifampin administration resulted in a 27% decrease in the mean moxifloxacin AUC0-24 and a marked increase in the AUC0-24 of the microbiologically inactive M1 metabolite. Additional studies are required to understand the clinical significance of the moxifloxacin-rifampin interaction.

Original languageEnglish (US)
Pages (from-to)2861-2866
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume51
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

MDR Genes
Rifampin
moxifloxacin
Confidence Intervals
Therapeutic Equivalency
P-Glycoprotein
Pharmaceutical Preparations
Sulfates

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. / Weiner, Marc H; Burman, William; Luo, Chi Cheng; Peloquin, Charles A.; Engle, Melissa; Goldberg, Stefan; Agarwal, Vipin; Vernon, Andrew.

In: Antimicrobial Agents and Chemotherapy, Vol. 51, No. 8, 08.2007, p. 2861-2866.

Research output: Contribution to journalArticle

Weiner, MH, Burman, W, Luo, CC, Peloquin, CA, Engle, M, Goldberg, S, Agarwal, V & Vernon, A 2007, 'Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin', Antimicrobial Agents and Chemotherapy, vol. 51, no. 8, pp. 2861-2866. https://doi.org/10.1128/AAC.01621-06
Weiner, Marc H ; Burman, William ; Luo, Chi Cheng ; Peloquin, Charles A. ; Engle, Melissa ; Goldberg, Stefan ; Agarwal, Vipin ; Vernon, Andrew. / Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. In: Antimicrobial Agents and Chemotherapy. 2007 ; Vol. 51, No. 8. pp. 2861-2866.
@article{401892d742944cb8abf7fd170beca47a,
title = "Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin",
abstract = "Treatment regimens combining moxifloxacin and rifampin for drug-susceptible tuberculosis are being studied intensively. However, rifampin induces enzymes that transport and metabolize moxifloxacin. We evaluated the effect of rifampin and the human multidrug resistance gene (MDR1) C3435T polymorphisms (P-glycoprotein) on moxifloxacin pharmacokinetic parameters. This was a single-center, sequential design study with 16 volunteers in which sampling was performed after four daily oral doses of moxifloxacin (400 mg) and again after 10 days of combined rifampin (600 mg) and moxifloxacin. After daily coadministration of rifampin, the area under the concentration-time curve from 0 to 24 h (AUC0-24) for moxifloxacin decreased 27{\%}. Average bioequivalence between moxifloxacin coadministered with rifampin and moxifloxacin alone was not demonstrated: the ratio of geometric means (RGM) of the moxifloxacin AUC0-24 was 73.3 (90{\%} confidence intervals [CI], 64.3, 83.5) (total P value, 0.87 for two one-sided t tests). Peak moxifloxacin concentrations, however, were equivalent: the RGM of the maximum concentration of the drug in serum was 93.6 (90{\%} CI, 80.2, 109.3) (total P value, 0.049). Concentrations of the sulfate conjugate metabolite of moxifloxacin were increased twofold following rifampin coadministration (AUC0-24, 1.29 versus 2.79 μg·h/ml). Concomitant rifampin administration resulted in a 27{\%} decrease in the mean moxifloxacin AUC0-24 and a marked increase in the AUC0-24 of the microbiologically inactive M1 metabolite. Additional studies are required to understand the clinical significance of the moxifloxacin-rifampin interaction.",
author = "Weiner, {Marc H} and William Burman and Luo, {Chi Cheng} and Peloquin, {Charles A.} and Melissa Engle and Stefan Goldberg and Vipin Agarwal and Andrew Vernon",
year = "2007",
month = "8",
doi = "10.1128/AAC.01621-06",
language = "English (US)",
volume = "51",
pages = "2861--2866",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

AU - Weiner, Marc H

AU - Burman, William

AU - Luo, Chi Cheng

AU - Peloquin, Charles A.

AU - Engle, Melissa

AU - Goldberg, Stefan

AU - Agarwal, Vipin

AU - Vernon, Andrew

PY - 2007/8

Y1 - 2007/8

N2 - Treatment regimens combining moxifloxacin and rifampin for drug-susceptible tuberculosis are being studied intensively. However, rifampin induces enzymes that transport and metabolize moxifloxacin. We evaluated the effect of rifampin and the human multidrug resistance gene (MDR1) C3435T polymorphisms (P-glycoprotein) on moxifloxacin pharmacokinetic parameters. This was a single-center, sequential design study with 16 volunteers in which sampling was performed after four daily oral doses of moxifloxacin (400 mg) and again after 10 days of combined rifampin (600 mg) and moxifloxacin. After daily coadministration of rifampin, the area under the concentration-time curve from 0 to 24 h (AUC0-24) for moxifloxacin decreased 27%. Average bioequivalence between moxifloxacin coadministered with rifampin and moxifloxacin alone was not demonstrated: the ratio of geometric means (RGM) of the moxifloxacin AUC0-24 was 73.3 (90% confidence intervals [CI], 64.3, 83.5) (total P value, 0.87 for two one-sided t tests). Peak moxifloxacin concentrations, however, were equivalent: the RGM of the maximum concentration of the drug in serum was 93.6 (90% CI, 80.2, 109.3) (total P value, 0.049). Concentrations of the sulfate conjugate metabolite of moxifloxacin were increased twofold following rifampin coadministration (AUC0-24, 1.29 versus 2.79 μg·h/ml). Concomitant rifampin administration resulted in a 27% decrease in the mean moxifloxacin AUC0-24 and a marked increase in the AUC0-24 of the microbiologically inactive M1 metabolite. Additional studies are required to understand the clinical significance of the moxifloxacin-rifampin interaction.

AB - Treatment regimens combining moxifloxacin and rifampin for drug-susceptible tuberculosis are being studied intensively. However, rifampin induces enzymes that transport and metabolize moxifloxacin. We evaluated the effect of rifampin and the human multidrug resistance gene (MDR1) C3435T polymorphisms (P-glycoprotein) on moxifloxacin pharmacokinetic parameters. This was a single-center, sequential design study with 16 volunteers in which sampling was performed after four daily oral doses of moxifloxacin (400 mg) and again after 10 days of combined rifampin (600 mg) and moxifloxacin. After daily coadministration of rifampin, the area under the concentration-time curve from 0 to 24 h (AUC0-24) for moxifloxacin decreased 27%. Average bioequivalence between moxifloxacin coadministered with rifampin and moxifloxacin alone was not demonstrated: the ratio of geometric means (RGM) of the moxifloxacin AUC0-24 was 73.3 (90% confidence intervals [CI], 64.3, 83.5) (total P value, 0.87 for two one-sided t tests). Peak moxifloxacin concentrations, however, were equivalent: the RGM of the maximum concentration of the drug in serum was 93.6 (90% CI, 80.2, 109.3) (total P value, 0.049). Concentrations of the sulfate conjugate metabolite of moxifloxacin were increased twofold following rifampin coadministration (AUC0-24, 1.29 versus 2.79 μg·h/ml). Concomitant rifampin administration resulted in a 27% decrease in the mean moxifloxacin AUC0-24 and a marked increase in the AUC0-24 of the microbiologically inactive M1 metabolite. Additional studies are required to understand the clinical significance of the moxifloxacin-rifampin interaction.

UR - http://www.scopus.com/inward/record.url?scp=34547639372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547639372&partnerID=8YFLogxK

U2 - 10.1128/AAC.01621-06

DO - 10.1128/AAC.01621-06

M3 - Article

VL - 51

SP - 2861

EP - 2866

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -